3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Tumor-Agnostic
1
Thoracic
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Pancreatic Neoplasms
1
Melanoma
1
Breast Neoplasms
1
Interventions
pembrolizumab
326
Nivolumab
289
Ipilimumab
260
Cyclophosphamide
194
aldesleukin
145
Interleukin-2
109
fludarabine phosphate
107
Temozolomide
83
fludarabine
81
Dacarbazine
81
Radiotherapy
74
trametinib
73
Vemurafenib
69
dabrafenib
66
Biopsy
65
sargramostim
50
Bevacizumab
50
Radiosurgery
49
Paclitaxel
49
Peripheral Blood Stem Cell Transplantation
48
Magnetic Resonance Spectroscopy
48
Carboplatin
48
Imiquimod
47
Aminolevulinic Acid
47
binimetinib
45
Cisplatin
45
CTLA-4 Antigen
43
cemiplimab
42
atezolizumab
41
Specimen Handling
41
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
LY3300054
×
Dermatologic
×
Clear all
NCT02791334
2024-09-27
PACT
Eli Lilly and Company
Phase 1
Completed
164 enrolled